Thiotepa - Sumitomo Dainippon Pharma

Drug Profile

Thiotepa - Sumitomo Dainippon Pharma

Alternative Names: DSP 1958

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sumitomo Dainippon Pharma
  • Class Antineoplastics; Myeloablative agonists; Organothiophosphorus compounds
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Solid tumours
  • Phase I Haematological disorders

Most Recent Events

  • 03 Jul 2018 Preregistration for Solid tumours (In adolescents, In children, In adults) in Japan (IV)
  • 30 Sep 2017 Sumitomo Dainippon Pharma completes a phase I pharmacokinetic trial for Haematological disorders (In children, In adults, In adolescents) in Japan (IV) (JapicCTI163433)
  • 01 Sep 2017 Sumitomo Dainippon Pharma initiates enrolment in a phase I trial for Solid tumours and Lymphoma (In children, In adolescents, In adults) in Japan (IV) (JapicCTI-173654)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top